Thus, pharmacologic or genetic targeting of SP family proteins would rebalance the immune landscape in gastric cancers by reducing SP-associated immunosuppressive infiltrating cells and shifting toward an activated T cell phenotype—resulting in increased sensitivity to immunotherapy [38, 50, 51]. This evidence concerns the gene TFF2 and gastric cancer.